CN105213425A - One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof - Google Patents
One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof Download PDFInfo
- Publication number
- CN105213425A CN105213425A CN201510732841.6A CN201510732841A CN105213425A CN 105213425 A CN105213425 A CN 105213425A CN 201510732841 A CN201510732841 A CN 201510732841A CN 105213425 A CN105213425 A CN 105213425A
- Authority
- CN
- China
- Prior art keywords
- parts
- reserpine
- oral cavity
- compound recipe
- cavity disintegration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to pharmaceutical field, be specifically related to one and treated hypertensive compound recipe reserpine drug port cavity disintegrating tablet and preparation method thereof.Described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, vitamin B1? 1 part, vitamin B6? 1 part, stabilizing agent fumaric acid 2-10 part and other pharmaceutic adjuvants.Experimental result shows that this drug port cavity disintegrating tablet onset time is short, and duration of efficacy is long, is convenient to patient's long-term treatment, improve drug safety, formulation and technology robustness is strong simultaneously, not by the impact of ambient temperature and humidity, significantly reduces the stability of preparation differences between batches and raising sample.
Description
Technical field
The present invention relates to pharmaceutical field about drug preparation technique, particularly relate to one and treat hypertensive compound recipe reserpine drug port cavity disintegrating tablet and preparation method thereof.
Background technology
Reserpine is adrenergic neuron barrier antihypertensive, by exhausting the epinephrine of SNE around, the catecholamine in the heart, brain and hetero-organization thereof and 5-hydroxy tryptamine reach the effect of resisting hypertension, decreased heart rate and suppression central nervous system.Be widely used in treatment that is slight and moderate hypertension; Blood pressure lowering and tranquilizer, hypotensive effect onset is slow, but persistent, after drug withdrawal, event resolves is also slow, and particularly having share good effect with thiazide diuretic, is one of main component of conventional compound hypertension medicine.Hydralazine hydrochloride is vasodilator, alignment degree essential hypertension, and hydralazine merges application diuretic and beta-blocker then can obtain good efficacy.Cyclopenthiazide is middle effect diuretic, also has hypotensive effect, and medication, in early days due to diuresis, reduces blood volume and blood pressure lowering, slightly loses sodium, the low sodium of small artery parietal cell, pass through Na in medication later stage body
+-Ca
2+exchanging mechanism makes Ca in cell
2+amount reduces, and blood vessel reduces the reactivity of vaso-excitor material, and causes vasodilation, blood pressure drops; This product also has the hypotensive effect strengthening other depressor.Hydrochlorothiazide is thiazide diuretic, antihypertensive, and when share with depressor, hypotensive effect is obviously strengthened.By reserpine and vasodilator, diuretic use in conjunction has synergism significantly, promotes blood pressure drops, improves curative effect, reduce dosage and the untoward reaction of each medicine; Hydrochlorothiazide and cyclopenthiazide all can increase the hypotensive effect of reserpine and hydralazine hydrochloride in addition, reduce the side effect of water-sodium retention.Promethazine hydrochloride is antihistaminic, competitively can block H
1receptor and produce antihistamine effect, has maincenter sedation.Rutin belongs to vitamin drug, has the effect reducing capillary permeability and fragility, keeps and recovers the normal elasticity of blood capillary, for preventing and treating hypertensive cerebral hemorrhage, can effectively suppress hematoblastic gathering, preventing thrombotic effect.
Fumaric acid is the simplest unsaturated dicarboxylic acid, also known as Fumaric acid, find from Rhizoma Corydalis the earliest, a kind of food additive---acidic flavoring agent of Chang Zuowei, for refreshment drink, Fruit candy, fruit jelly, ice cream etc., also Chang Zuowei pharmaceutic adjuvant is used for pharmaceutical industry, can be used as acidity regulator, antioxidation auxiliary agent etc.According to MDINDIA website, fumarate is used for the treatment of severe psoriasis always.Nowadays, research worker finds, this medicine can also help prevent multiple sclerosis (MS).This research is published on current neurological's magazine " Brain ".Now, the neurosurgeon of Bo Hong Rule university (RUB) finds, fumarate discharges free radical in eliminate the inflammation process, thus neuroprotective and glial cell.
Oral cavity disintegration tablet refers to that a kind of being placed on lingual surface disintegrate can become the new medicinal preparation of countless microgranule and sweet mouthfeel in 30 seconds automatically.Because its disintegration rate is fast, absorb rapidly, and need not water delivery service be used when taking medicine, saliva can make its disintegrate or dissolving, both can swallow by conventional tablet, can be placed in water again and take after disintegrate, also can not need to take medicine with water swallow, be particularly useful for old man, children's, some especial patients (psychosis, senile dementia, epileptic patient etc.) and the inconvenient person that fetches water and take medicine and provide conveniently.Certain method can be adopted in the preparation to improve the mouthfeel of preparation simultaneously, greatly can improve the drug compliance of child patient, solve the problem of taking baby ' difficulty.But oral cavity disintegration tablet usually exists following shortcoming: the sensory issues of medicine, as difficult problems such as sand types; The packed and transported problem caused because hardness is too low.
Compound recipe reserpine oral cavity disintegration tablet is normally by reserpine, hydrochlorothiazide, vitamin B
6, potassium chloride, vitamin B
1, hydralazine, the Multiple components such as promethazine hydrochloride composition compound oral disintegrating tablet formulation, such compound oral disintegrating tablet formulation has been applied for many years clinically, and effectiveness and safety have obtained sufficient checking.But owing to there is vitamin B in prescription
6, vitamin B
1, hydralazine, rutin etc., less stable, is easily affected by the external environment (as temperature, illumination, oxygen etc.) and changes, and medicament contg reduces.Have research worker to be studied for compound recipe reserpine oral cavity disintegration tablet medicine unstability situation, but the result obtained is barely satisfactory often.
The Chinese patent application of application number CN201110369547 adopts and adds acidic materials dihydric phosphate to maintain the stability of effective ingredient in compound recipe Reserpoid, is through trial, although this inorganic acidic materials can improve vitamin B
6and vitamin B
1stability, but improve helpless to the stability of hydralazine and rutin.The Chinese patent application of application number CN201210455548 adopts vitamin B
1carry out the mode of coating to improve vitamin B
1stability, but really to unstability active component vitamin B
6, hydralazine, rutin etc. do not consider, simultaneously to vitamin B
1carry out coating and too increase processing step flow process, add a large amount of work.
In hypertensive treatment, the fluctuation of blood pressure in the pressure reduction of hypertension of conventional buck medicine is large, and medication effect is poor, and side effect is large, and onset time is long, and duration of efficacy is short.In addition, in compound recipe reserpine Orally disintegrating slice prescription, comprise reserpine and cyclopenthiazide medicament contg is extremely low, more than 30 times are differed from the active component of other lower contents, with the active component difference thousands of times of other high level, very easily cause the medicament contg uniformity against regulation, by suitable method, the medicament contg uniformity improving active component obtains each index all satisfactory compound recipe reserpine orally disintegrating tablet preparation.Simultaneously, for solving the compliance improving hypertensive patient, we have employed new prescription, new technology and new spec with various active composition for principal agent, ensureing under the prerequisite playing drug effect and safety, prepare the oral cavity disintegration tablet that is applicable to hyperpietic and further optimization has been carried out to prescription and technique, this dosage form prepared by the method without the need to water also without the need to chewing, medicine is put into mouth and is met saliva just rapid disintegrate, mouthfeel is good, without grittiness, just can enter stomach onset by simple swallowing act, greatly comply with the feature of taking medicine of hyperpietic.The present invention adopts and a kind ofly can meet industrialized technology and prepare stable active ingredient particle, add tabletting after other adjuvant, be prepared from disintegration time within 30 seconds, and tablet pressure can reach the preparation being conducive to packing and transport of more than 40N, the preparation method of said preparation is simple, drug substance stable good, repeatability is high, be easy to large-scale production.
Summary of the invention
The object of the invention is the defect existed for FUFANG LIXUEPING PIAN formula traditional preparation methods, provide a kind of with reserpine, hydrochlorothiazide, vitamin B
6, potassium chloride, the various active composition such as rutin one treat hypertensive compound recipe reserpine medicine orally disintegrating tablet preparation and preparation method thereof.The compound recipe reserpine medicine orally disintegrating tablet preparation toxic and side effects utilizing technical solution of the present invention to prepare is few, and in pressure reduction, fluctuation of blood pressure is little, and onset time is short, duration of efficacy is long, be convenient to patient's long-term treatment, improve drug safety, and improve the compliance of medication.The present invention have employed new recipe and the hypertensive compound recipe reserpine medicine orally disintegrating tablet preparation of new technology preparation treatment simultaneously, significantly reduces the stability that preparation criticizes a uniformity and stripping difference and raising sample.
Another object of the present invention is the compound recipe reserpine oral cavity disintegration tablet providing one kind of multiple active component, not only stripping is rapid, disintegration time is short and mouthfeel is good for this oral cavity disintegration tablet, without grittiness, just stomach onset can be entered by simple swallowing act, greatly comply with the pathological characteristic of hyperpietic, be applicable to the treatment of hyperpietic's especially aged patients with hypertension of dysphagia.
The technical solution used in the present invention is:
The invention provides one and treat hypertensive compound recipe reserpine oral cavity disintegration tablet, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 2-10 part, polyacrylic resin IV10-40 part and other optional acceptable pharmaceutic adjuvants of one or more pharmacy.
Compound recipe reserpine oral cavity disintegration tablet of the present invention, is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 3-7 part, polyacrylic resin IV15-30 part and other optional acceptable pharmaceutic adjuvants of one or more pharmacy.
Compound recipe reserpine oral cavity disintegration tablet of the present invention, is characterized in that: the acceptable pharmaceutic adjuvant of described pharmacy is any one or more in filler, disintegrating agent, binding agent, correctives and lubricant
Compound recipe reserpine oral cavity disintegration tablet of the present invention, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 3-7 part, polyacrylic resin IV15-30 part, filler 30-150 part, disintegrating agent 2-5 part, binding agent 3-10 part, correctives 0-8 part and lubricant 0.5-2 part.
Compound recipe reserpine oral cavity disintegration tablet of the present invention, is characterized in that:
Described filler is any one or more in mannitol, lactose, sucrose, dextrin, starch, microcrystalline Cellulose, Sargassum polysaccharides and chitosan;
Described disintegrating agent is any one or more in carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and carboxymethylcellulose calcium;
Described binding agent is any one or more in Opadry, hypromellose, hydroxypropyl cellulose, polyvidone, polyvinyl alcohol and sodium carboxymethyl cellulose;
Described correctives is selected from one or more of essence and flavoring agent of aspartame, acesulfame potassium, saccharin sodium, glucosan, stevioside, citric acid, various fragrance;
Described lubricant is any one or more in Pulvis Talci, hydrogenated vegetable oil, micropowder silica gel, sodium stearyl fumarate, calcium stearate, sodium lauryl sulphate, magnesium stearate and stearyl alcohol;
Compound recipe reserpine oral cavity disintegration tablet of the present invention, is characterized in that:
Filler preferably microcrystalline cellulose in described compound recipe reserpine oral cavity disintegration tablet and/or mannitol, the preferred cross-linking sodium carboxymethyl cellulose of disintegrating agent, the preferred hydroxypropyl cellulose of binding agent, the preferred aspartame of correctives, the preferred sodium stearyl fumarate of lubricant and/or magnesium stearate.
Compound recipe reserpine oral cavity disintegration tablet of the present invention, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 4-6 part, polyacrylic resin IV15-25 part, microcrystalline Cellulose and/or mannitol 90-100 part, cross-linking sodium carboxymethyl cellulose 3-4 part, hydroxypropyl cellulose 4-6 part, aspartame 4-6 part and sodium stearyl fumarate and/or magnesium stearate 1-2 part.
Compound recipe reserpine oral cavity disintegration tablet of the present invention, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 5 parts, polyacrylic resin IV20 part, 91.3 parts, mannitol, cross-linking sodium carboxymethyl cellulose 3.6 parts, hydroxypropyl cellulose 5 parts, aspartame 5 parts and magnesium stearate 1 part.
The preparation method of compound recipe reserpine oral cavity disintegration tablet of the present invention, it is characterized in that: first the reserpine of recipe quantity, cyclopenthiazide and hydroxypropyl cellulose are dissolved in ethanol, rest activity composition and fumaric acid add in fluidized bed granulation seed-coating machine, spray into above-mentioned alcoholic solution after fluidisation mixing to granulate, the alcoholic solution of polyacrylic resin IV is sprayed into after completing, terminate post-drying, add filler, disintegrating agent, correctives and mix lubricant after granulate evenly, tabletting and get final product.
(1) oral cavity disintegration tablet prescription
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 50g, polyacrylic resin IV200g, mannitol 913g, cross-linking sodium carboxymethyl cellulose 36g, hydroxypropyl cellulose 50g, aspartame 50g part and magnesium stearate 10g.
(2) preparation process
Take reserpine and the cyclopenthiazide of recipe quantity, add in 95% ethanol 1000ml, after stirring and dissolving to clarification, take the hydroxypropyl cellulose of recipe quantity, add in above-mentioned alcoholic solution, stir to clarify, for subsequent use.
Take the polyacrylic resin IV of recipe quantity, add in 95% ethanol 2000ml, after stirring and dissolving to clarification, for subsequent use.
By hydralazine hydrochloride, hydrochlorothiazide, promethazine hydrochloride, potassium chloride, rutin, Arechin (Polfa), vitamin B
1, vitamin B
6pulverize respectively with fumaric acid, sieve 80 eye mesh screens, take the above-mentioned supplementary material of recipe quantity, after equal increments method mix homogeneously, add in fluidized bed granulation seed-coating machine, preheating, regulate stream temperature to 40 DEG C, dry air flow 100m
3* h
-1, get the hydroxypropyl cellulose alcoholic solution of above-mentioned active component, pump into aerochamber atomization with peristaltic pump with the flow velocity of top spray mode 5ml/min to granulate, atomizing pressure is 1.4bar, progressively improve and pump into speed and be finished to coating solution to 40ml/min, the alcoholic solution of polyacrylic resin IV is pumped into aerochamber atomization in top spray mode and granulates by continuation peristaltic pump, stream temperature is improved to 50 DEG C after terminating, continue fluidized drying in fluid bed to take out after 45 minutes, choose and be less than 18 order granules, after passed examination, add the filler of recipe quantity, disintegrating agent, after correctives mixes 30 minutes, add lubricant, mixing 5min, tabletting, pack.
The preparation method of compound recipe reserpine oral cavity disintegration tablet of the present invention, is characterized in that: the tablet pressure of gained is at more than 40N; This oral cavity disintegration tablet in the intraoral disintegration time within 30 seconds, and without bitter.
Positive beneficial effect of the present invention:
(1) the compound recipe reserpine oral cavity disintegration tablet taking convenience utilizing technical solution of the present invention to prepare, have no side effect, mouthfeel is good, without grittiness, be convenient to patient's long-term treatment, greatly comply with the pathological characteristic of hyperpietic, be applicable to the treatment of hyperpietic's especially aged patients with hypertension of dysphagia.The compound recipe reserpine orally disintegrating tablet preparation utilizing technical solution of the present invention to prepare solves hydralazine hydrochloride, rutin, vitamin B1 and vitamin B6 etc. in Orally disintegrating slice prescription and there is the problem of chemically unstable; Improve the stability of orally disintegrating tablet preparation, reduce toxic and side effects, ensure that quality and curative effect simultaneously; Improve the standard of original compound recipe Reserpoid, complied with the compliance of hyperpietic, and preparation technology is applicable to industrialized requirement.The present inventor verifies the fumaric acid increasing the amount of selecting in active substance through lot of experiments, and join in compound recipe reserpine Orally disintegrating tablet recipe according to above-mentioned consumption, make them create synergism, significantly improve the stability of curative effect and this compound recipe reserpine oral cavity disintegration tablet.
(2) the compound recipe reserpine oral cavity disintegration tablet that prepared by technical solution of the present invention has the obvious improving SNR of abnormal flavour such as bitterness for compound recipe reserpine active component, it improves mouthfeel principle and is mainly the powder coating taste masking and taste masking technology that use time prepared by the present invention, selected adjuvant and preparation method are all easy to get feasible, be suitable for expanding suitability for industrialized production, the method adopted has good repeatability.The particularly preferred formula of the present invention and preparation method, is through the preferred plan that screening obtains, selects the prescription of optimization, adopts fluidized bed powder coating method, and compression produces oral cavity disintegration tablet, can realize the obvious mouthfeel of oral cavity disintegration tablet and improve effect.The compound recipe reserpine orally disintegrating tablet preparation utilizing technical solution of the present invention to prepare, show through clinical experimental study, compared with the compound recipe Reserpoid that goes on the market, in hypertensive pressure reduction, fluctuation of blood pressure is less, improve the therapeutic effect of medicine, extend duration of efficacy, reducing gastrointestinal stimulates and blood plasma drug concentration peak value, reduce the possibility had side effects, improve the compliance of patient medication.
(3) the compound recipe reserpine orally disintegrating tablet preparation toxic and side effects utilizing technical solution of the present invention to prepare is few, and in pressure reduction, fluctuation of blood pressure is little, and onset time is short, and duration of efficacy is long, is convenient to patient's long-term treatment, improves drug safety.The present invention have employed new recipe simultaneously and new technology prepares compound recipe reserpine orally disintegrating tablet preparation, significantly reduces the stability of preparation differences between batches and raising sample.Compound recipe reserpine orally disintegrating tablet preparation of the present invention is seldom subject to the impact of gastric emptying change in vivo, absorption in vivo has good repeatability, the risk that may cause medicine pulse due to uniformity of dosage units and dissolution difference can be avoided, reduce and may to cause weakness, weakness, confusion, hypotension, dizzy, heart block due to medicine pulse, even cause death, improve drug safety.
(4) the stripping feature of the compound recipe reserpine orally disintegrating tablet preparation utilizing technical solution of the present invention to prepare comparatively prior art has and improves significantly, and bioavailability is high, and individual variation is little; Obtained solid oral disintegrating tablet formulation has preferably uniformity of dosage units and good stability.Have employed new recipe and the hypertensive compound recipe reserpine medicine orally disintegrating tablet preparation of new technology preparation treatment simultaneously, significantly reduce the stability that preparation criticizes a uniformity and stripping difference and raising sample, obtained compound recipe reserpine orally disintegrating tablet preparation uniformity of dosage units and dissolution all meet the requirement of 2015 editions Chinese Pharmacopoeias.Evaluation is investigated by modes such as oral cavity disintegration tablet dissolution and disintegration time measuring, ocular estimate, the evaluations of volunteer mouthfeel, not only stripping is rapid, disintegration time is short and good mouthfeel to find compound recipe reserpine oral cavity disintegration tablet provided by the invention, greatly comply with the pathological characteristic of aged patients with hypertension
(5) technical solution of the present invention prepare compound recipe reserpine oral cavity disintegration tablet, preparation process is simple for process, adopt fluidized bed powder coating method and tablet forming technique, productive rate reaches more than 95%, and product effect is high, meets large requirement of producing, under laboratory scale, the amplification that can complete 30000 units is produced, and production efficiency is high, can prepare the compound recipe reserpine oral cavity disintegration tablet of multiple different size; Meanwhile, this technique prepared the oral cavity disintegration tablet disintegration time of gained within 30 seconds, and pressure can reach more than 40N be conducive to pack, transport and the carrying of patient.
(6) the compound recipe reserpine orally disintegrating tablet preparation utilizing technical solution of the present invention to prepare solves reserpine, cyclopenthiazide etc. because of content and is seldom not easy the problem of mix homogeneously, production technology adopts totally-enclosed fluidized bed granulation technique, decrease pollution, decrease the contact with water, light, thermal source simultaneously, avoid influencing each other of chemical drugs in formula, thus ensure that quality and the curative effect of product.Selected supplementary material and preparation method are all easy to get feasible, and be suitable for expanding suitability for industrialized production, the method adopted has good repeatability.The particularly preferred formula of the present invention and preparation method, is through the preferred plan that screening obtains, selects the prescription of optimization, adopts fluidized bed granulation method to prepare compound recipe reserpine orally disintegrating tablet preparation, can realize the release performance that this dosage form is good in vivo.
(7) product compound recipe reserpine oral cavity disintegration tablet of the present invention, investigates through accelerated stability test, and in 12 months, character stable, medicament contg, related substance is all in controlled range, and suitability for industrialized is produced.
Four, detailed description of the invention:
Be below the specific embodiment of the present invention, embodiment is for further describing the present invention instead of restriction the present invention.The technical scheme of equivalence all and of the present invention all belongs to protection scope of the present invention.
embodiment 1 FUFANG LIXUEPING PIAN and preparation method thereof
First the reserpine of recipe quantity, cyclopenthiazide and hydroxypropyl cellulose are dissolved in ethanol, all the other adjuvants except lubricant add in fluidized bed granulation seed-coating machine, after spraying into the granulation of above-mentioned alcoholic solution, dry after fluidisation mixing, mix lubricant is added even, tabletting and get final product after granulate.
(1) oral cavity disintegration tablet prescription
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 50g, polyacrylic resin IV200g, mannitol 913g, cross-linking sodium carboxymethyl cellulose 36g, hydroxypropyl cellulose 50g, aspartame 50g part and magnesium stearate 10g.
(2) preparation process
Take reserpine and the cyclopenthiazide of recipe quantity, add in 95% ethanol 1000ml, after stirring and dissolving to clarification, take the hydroxypropyl cellulose of recipe quantity, add in above-mentioned alcoholic solution, stir to clarify, for subsequent use.
Take the polyacrylic resin IV of recipe quantity, add in 95% ethanol 2000ml, after stirring and dissolving to clarification, for subsequent use.
By hydralazine hydrochloride, hydrochlorothiazide, promethazine hydrochloride, potassium chloride, rutin, Arechin (Polfa), vitamin B
1, vitamin B
6pulverize respectively with fumaric acid, sieve 80 eye mesh screens, take the above-mentioned supplementary material of recipe quantity, after equal increments method mix homogeneously, add in fluidized bed granulation seed-coating machine, preheating, regulate stream temperature to 40 DEG C, dry air flow 100m
3* h
-1, get the hydroxypropyl cellulose alcoholic solution of above-mentioned active component, pump into aerochamber atomization with peristaltic pump with the flow velocity of top spray mode 5ml/min to granulate, atomizing pressure is 1.4bar, progressively improve and pump into speed and be finished to coating solution to 40ml/min, the alcoholic solution of polyacrylic resin IV is pumped into aerochamber atomization in top spray mode and granulates by continuation peristaltic pump, stream temperature is improved to 50 DEG C after terminating, continue fluidized drying in fluid bed to take out after 45 minutes, choose and be less than 18 order granules, after passed examination, add the filler of recipe quantity, disintegrating agent, after correctives mixes 30 minutes, add lubricant, mixing 5min, tabletting, pack.
Illustrate: the purified water that the present embodiment adds and ethanol are through preparation method, and final drying obtains product, its purified water added and ethanol all evaporate;
embodiment 2 FUFANG LIXUEPING PIAN and preparation method thereof
Substantially the same manner as Example 1, difference is:
The prescription of FUFANG LIXUEPING PIAN of the present invention consists of:
Reserpine 0.6g, hydralazine hydrochloride 20g, cyclopenthiazide 0.5g, hydrochlorothiazide 30g, promethazine hydrochloride 40g, potassium chloride 600g, rutin 100g, Arechin (Polfa) 50g, vitamin B12 0g, vitamin B6 20g, fumaric acid 120g, polyacrylic resin IV500g, mannitol 913g, microcrystalline Cellulose 913g, cross-linking sodium carboxymethyl cellulose 70g, hydroxypropyl cellulose 100g, aspartame 80g part and sodium stearyl fumarate 30g.
Illustrate: the purified water that the present embodiment adds and ethanol are through preparation method, and final drying obtains product, its purified water added and ethanol all evaporate;
The preparation process of FUFANG LIXUEPING PIAN of the present invention is with embodiment 1.
embodiment 3 FUFANG LIXUEPING PIAN and preparation method thereof
Substantially the same manner as Example 1, difference is:
The prescription of FUFANG LIXUEPING PIAN of the present invention consists of:
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 70g, polyacrylic resin IV300g, mannitol 1000g, cross-linking sodium carboxymethyl cellulose 35g, hydroxypropyl cellulose 40g, aspartame 50g, citric acid 50g and magnesium stearate 10g.
Illustrate: the purified water that the present embodiment adds and ethanol are through preparation method, and final drying obtains product, its purified water added and ethanol all evaporate;
The preparation process of FUFANG LIXUEPING PIAN of the present invention is with embodiment 1.
embodiment 4 FUFANG LIXUEPING PIAN and preparation method thereof
Substantially the same manner as Example 1, difference is:
The prescription of FUFANG LIXUEPING PIAN of the present invention consists of:
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 50g, polyacrylic resin IV250g, Sargassum polysaccharides 1000g, low-substituted hydroxypropyl cellulose 50g, hydroxypropyl cellulose 70g and magnesium stearate 8g.
Illustrate: the purified water that the present embodiment adds and ethanol are through preparation method, and final drying obtains product, its purified water added and ethanol all evaporate;
The preparation process of FUFANG LIXUEPING PIAN of the present invention is with embodiment 1.
embodiment 5 FUFANG LIXUEPING PIAN and preparation method thereof
Substantially the same manner as Example 1, difference is:
The prescription of FUFANG LIXUEPING PIAN of the present invention consists of:
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 70g, polyacrylic resin IV150g, mannitol 800g, polyvinylpolypyrrolidone 50g, polyvidone 40g, acesulfame potassium 30g, citric acid 30g and calcium stearate 10g.
Illustrate: the purified water that the present embodiment adds and ethanol are through preparation method, and final drying obtains product, its purified water added and ethanol all evaporate;
The preparation process of FUFANG LIXUEPING PIAN of the present invention is with embodiment 1.
test example 1 compatibility test
By reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, respectively with potassium dihydrogen phosphate 5 parts, sodium dihydrogen phosphate 5 parts, citric acid 5 parts, 5 parts, tartaric acid, fumaric acid 5 parts, the materials such as fumaric acid 10 parts and above-mentioned mixture of active principles are granulated by after both certainty ratios respectively Homogeneous phase mixing, obtained granule is respectively charged in uncovered bottle, at comparatively exacting terms (60 DEG C of high temperature, 90%RH high humidity and 4500lx high light) under place 10 days, respectively at the 5th day and sampling in the 10th day, investigate sample property, the main standard items such as content have unchanged, and result was compared with 0 day, result of the test is in table 1.
[assay] lucifuge operates.
Reserpine, hydrochlorothiazide and promethazine hydrochloride measure according to high performance liquid chromatography (general rule CP20150512).
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; With 0.06mol/L potassium dihydrogen phosphate-methanol (90:10) (pH3.0) for mobile phase A, acetonitrile is Mobile phase B, and according to the form below carries out gradient elution; Determined wavelength is 268nm.Number of theoretical plate calculates by reserpine peak and is not less than 3000, and each main peak and the peak-to-peak separating degree of other chromatographs should meet the requirements.
| Time (minute) | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 100 | 0 |
| 4 | 100 | 0 |
| 7 | 65 | 35 |
| 20 | 65 | 35 |
| 21 | 100 | 0 |
| 25 | 100 | 0 |
Algoscopy gets this product 10, put in 25ml measuring bottle respectively, [(get sodium acetate 9.0g, the 1000ml that adds water makes dissolving to sodium acetate solution, adds triethylamine 3.0ml to add diluent, by glacial acetic acid adjust ph to 5.0)-acetonitrile (55:45)] ultrasonicly make dissolving and be diluted to scale, shake up, filter, get subsequent filtrate as need testing solution, precision measures 20 μ l and notes people's chromatograph of liquid, record chromatogram; Separately get reserpine reference substance, hydrochlorothiazide reference substance and promethazine hydrochloride reference substance in right amount each, accurately weighed, add diluent dissolve and quantitatively dilute the solution making Esidri 1.2 μ g, hydrochlorothiazide 60 μ g and promethazine hydrochloride 80 μ g in every lml, be measured in the same method.Go out the content of each component in every sheet by external standard method with calculated by peak area, and obtain the average content of each component in 10, to obtain final product.
Hydralazine hydrochloride, vitamin B
1with vitamin B
6according to high performance liquid chromatography, (CP2015 general rule 0512 > measures
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; Be mobile phase with buffer (0.11% sodium hexanesulfonate, 0.02% sodium heptanesulfonate mixed solution, by glacial acetic acid adjust ph to 3.5)-acetonitrile-methanol (80:10:10); Determined wavelength is 210nm.Number of theoretical plate calculates by hydralazine hydrochloride peak and is not less than 3000; The peak-to-peak separating degree of each chromatograph should meet the requirements.
Algoscopy gets this product 10, adds 0.1% phosphoric acid solution respectively appropriate, and grinding, is transferred in 100ml measuring bottle; jolting 30 minutes, is diluted to scale with 0.1% phosphoric acid solution, shakes up, centrifugal; get supernatant as need testing solution, precision measures 20 μ l injection liquid chromatographies, record chromatogram; Another precision takes hydralazine hydrochloride reference substance, vitamin B
1reference substance and vitamin B
6reference substance is in right amount each, adds 0.1% phosphoric acid solution dissolving and quantitatively dilute to make hydrochloric hydralazine 10 μ g, vitamin B in every lml
110 μ g and vitamin Bs
6the solution of 10 μ g, is measured in the same method.Go out the content of each component in every sheet by external standard method with calculated by peak area, and obtain the average content of each component in 10, to obtain final product.
Rutin is according to high performance liquid chromatography (CP2015 general rule 0512 >
Chromatographic condition and system suitability octadecylsilane chemically bonded silica are filler; With methanol-0.2mol/L acetic acid (40:60) for mobile phase; Flow velocity 1.0ml/min; Determined wavelength is 355nm.Number of theoretical plate calculates by rutin and is not less than 3000; The peak-to-peak separating degree of each chromatograph should meet the requirements.
Algoscopy gets this product 10 respectively, and porphyrize is put in 100mL measuring bottle, and add the flowing mutual-assistance and dissolve, filter, get subsequent filtrate, precision measures 10ml mobile phase and is diluted to 100mL.Shake up, filter, get subsequent filtrate as need testing solution, precision measures 20 μ l and notes people's chromatograph of liquid, record chromatogram; It is appropriate that another precision takes control substance of Rutin, adds mobile phase and dissolve and quantitatively dilute the solution made containing rutin 5 μ g in every lml, be measured in the same method.Go out the content of rutin in every sheet by external standard method with calculated by peak area, and obtain the average content of 10 middle rutins, to obtain final product.
Table 1 compatibility test result
As can be seen from the compatibility test result of upper table, the stability raising all in various degree of fumaric acid 5 parts of each active component is added in mixture of active principles, when adding fumaric acid 10 parts, the stability of vitamin B1, vitamin B6 and rutin obtains further raising, but the stability of hydralazine hydrochloride does not rise counter falling; Relative to the acidic materials of all the other bibliographical informations as potassium dihydrogen phosphate etc., the raising of fumaric acid to compound recipe reserpine Orally disintegrating tablet stability has clear superiority.
test example 2 uniformity of dosage units, dissolution and disintegration time mensuration
[Determination of Content Uniformity]
Reserpine, hydrochlorothiazide, promethazine hydrochloride, hydralazine hydrochloride, rutin, vitamin B
1with vitamin B
6
Lucifuge operates.By the every sheet cubage recorded under assay item, should conform with the regulations (CP2015 general rule 0941).
[dissolution]
Hydrochlorothiazide and promethazine hydrochloride
Lucifuge operates.Get this product; according to dissolution and drug release determination method (CP2015 general rule 0,931 second method); with O.lmol/L hydrochloric acid solution 900ml for dissolution medium; rotating speed is 50 turns per minute; operate in accordance with the law, through 30 minutes time, get solution and be about 10ml; filter with the microporous filter membrane in 0.45 μm of aperture, get subsequent filtrate as need testing solution; Another precision takes hydrochlorothiazide reference substance and promethazine hydrochloride reference substance is in right amount each, and under adding assay item, diluent dissolves and quantitatively dilutes the solution made containing hydrochlorothiazide 1.7 μ g, promethazine hydrochloride 2.2 μ g in every lml, product solution in contrast.Precision measures need testing solution and each 20 μ l of reference substance solution, except mobile phase is [0.06mol/L potassium dihydrogen phosphate-methanol (90:10) (pH3.0)]-acetonitrile (65:35), measure, by external standard method with the stripping quantity of hydrochlorothiazide and promethazine hydrochloride in the every sheet of calculated by peak area according to method under " reserpine, hydrochlorothiazide and promethazine hydrochloride " assay item.
[disintegration]
Get this product, with reference to inspection method disintegration (Chinese Pharmacopoeia version in 2010 two annex XA tablet inspection techniques), hanging basket is hung on metal rack by the stainless steel shaft of upper end, invade in 1000ml beaker, and screen cloth distance beaker bottom 25mm when regulating hanging basket position to make it decline, fill the water that temperature is 37 DEG C ± 1 DEG C in beaker, when regulating height of water level to make hanging basket increase, screen cloth is at 15mm place, underwater.Get test sample 6, be set up respectively and state in the glass tubing of hanging basket, start disintegration tester and check, start timing when contacting water from tablet, record granule is completely by the time of screen cloth.
Measurement result sees the following form:
Table 2 content, uniformity of dosage units and dissolution determination result
Bright by the summary analysis of the aspect such as uniformity of dosage units, dissolution, disintegration of compound recipe reserpine orally disintegrating tablet preparation obtained each embodiment, the compound recipe reserpine orally disintegrating tablet preparation disintegrate that the present invention obtains is rapid, release is fast, in 30 seconds, disintegrate is complete, can onset in time, uniformity of dosage units and dissolution all meet the requirement of 2015 editions Chinese Pharmacopoeias, improve the standard of original compound recipe Reserpoid, complied with the compliance of hyperpietic, and preparation technology is applicable to industrialized requirement.
test example 3 investigates the impact of the present composition on pigeon nausea model
1, laboratory animal: healthy pigeon, male and female dual-purpose, body weight 350 ± 50g, regular grade, is purchased from cultivation base.
2, Experimental agents and dosage:
Healthy pigeon 70, is divided into 7 groups at random.Experiment prospective adaptation is raised 1 week, normal diet drinking-water between feeding period, fasting 4h before experiment, and room temperature keeps 22 ~ 24 DEG C, keeps clean, well-ventilated.Respectively by each reagent group administration below, dosage is all same as 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals, or the starch of the amount identical with it (blank).Each index of close observation, water inlet of normally taking food after 8h.
(1) test group 1-3, is respectively the compound recipe reserpine oral cavity disintegration tablet of embodiment 1,2 and 3 by 3 groups, and dosage is 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals.
(2) control group A, 1 group, mixture of active principles, dosage is 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals.
(3) matched group B, 1 group, starch, dosage is 44mg starch/kg the weight of animals.
(4) matched group C, forms by supplementary material each in embodiment 1 physical mixture be mixed to get by 1 group, and dosage is 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals.
(5) matched group D, 1 group, commercially available FUFANG LIXUEPING PIAN, manufacturer's Roche, dosage is 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals.
3, experimental technique:
Observation index: vomiting incubation period (time of first time vomiting extremely occurs after showing medicine) occurs pigeon, vomiting number of times (show the number of times that every a burst of vomiting occurs after medicine, wherein a burst of vomiting refer to stretch neck from pigeon, dehisce, shrug, abdominal part be retracted to pigeon restore calm count 1 vomiting) and vomiting frequency (refer to every gust vomit pigeon stretch neck, dehisce, shrug, the number of times of abdominal part contraction).
Every animal pharmaceuticals 0.03mg reserpine (rest activity components in certain proportion)/kg the weight of animals is given through gavage by above grouping, vomit incubation period (min) after recording every animal gavage, record the vomiting number of times of every animal from gavage starts in 5 hours and vomiting frequency simultaneously.
In often organizing, there is the number of animals (n) of vomiting in statistics, for occurring that the animal of vomiting (including the vomiting of vomitus and the summation without the retch of vomitus) calculates their incubation period (min, ± s), average vomiting number of times and average vomiting frequency.The results are shown in following table:
Table 3 pigeon zoopery vomiting situation compares (± s, n=10)
From table 3, the vomiting animals that compound recipe reserpine oral cavity disintegration tablet of the present invention causes is few, and incubation period is long and vomit number of times and vomiting frequency is few.
Claims (10)
1. the hypertensive compound recipe reserpine oral cavity disintegration tablet for the treatment of, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 2-10 part, polyacrylic resin IV10-40 part and other optional acceptable pharmaceutic adjuvants of one or more pharmacy.
2. compound recipe reserpine oral cavity disintegration tablet according to claim 1, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 3-7 part, polyacrylic resin IV15-30 part and other optional acceptable pharmaceutic adjuvants of one or more pharmacy.
3. compound recipe reserpine oral cavity disintegration tablet according to claim 1 and 2, is characterized in that: the acceptable pharmaceutic adjuvant of described pharmacy is any one or more in filler, disintegrating agent, binding agent, correctives and lubricant.
4. compound recipe reserpine oral cavity disintegration tablet according to claim 3, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 3-7 part, polyacrylic resin IV15-30 part, filler 30-150 part, disintegrating agent 2-5 part, binding agent 3-10 part, correctives 0-8 part and lubricant 0.5-2 part.
5. the compound recipe reserpine oral cavity disintegration tablet according to claim 3 or 4, is characterized in that:
Described filler is any one or more in mannitol, lactose, sucrose, dextrin, starch, microcrystalline Cellulose, Sargassum polysaccharides and chitosan;
Described disintegrating agent is any one or more in carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and carboxymethylcellulose calcium;
Described binding agent is any one or more in Opadry, hypromellose, hydroxypropyl cellulose, polyvidone, polyvinyl alcohol and sodium carboxymethyl cellulose;
Described correctives is selected from one or more of essence and flavoring agent of aspartame, acesulfame potassium, saccharin sodium, glucosan, stevioside, citric acid, various fragrance;
Described lubricant is any one or more in Pulvis Talci, hydrogenated vegetable oil, micropowder silica gel, sodium stearyl fumarate, calcium stearate, sodium lauryl sulphate, magnesium stearate and stearyl alcohol.
6. compound recipe reserpine oral cavity disintegration tablet according to claim 5, is characterized in that:
Filler preferably microcrystalline cellulose in described compound recipe reserpine oral cavity disintegration tablet and/or mannitol, the preferred cross-linking sodium carboxymethyl cellulose of disintegrating agent, the preferred hydroxypropyl cellulose of binding agent, the preferred aspartame of correctives, the preferred sodium stearyl fumarate of lubricant and/or magnesium stearate.
7. compound recipe reserpine oral cavity disintegration tablet according to claim 6, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 4-6 part, polyacrylic resin IV15-25 part, microcrystalline Cellulose and/or mannitol 90-100 part, cross-linking sodium carboxymethyl cellulose 3-4 part, hydroxypropyl cellulose 4-6 part, aspartame 4-6 part and sodium stearyl fumarate and/or magnesium stearate 1-2 part.
8. compound recipe reserpine oral cavity disintegration tablet according to claim 7, it is characterized in that: described compound recipe reserpine oral cavity disintegration tablet is made up of the supplementary material of following parts by weight: reserpine 0.03 part, hydralazine hydrochloride 1 part, cyclopenthiazide 0.025 part, hydrochlorothiazide 1.5 parts, promethazine hydrochloride 2 parts, 30 parts, potassium chloride, rutin 5 parts, Arechin (Polfa) 2.5 parts, VB11 part, vitamin B6 1 part, fumaric acid 5 parts, polyacrylic resin IV20 part, 91.3 parts, mannitol, cross-linking sodium carboxymethyl cellulose 3.6 parts, hydroxypropyl cellulose 5 parts, aspartame 5 parts and magnesium stearate 1 part.
9. the preparation method of the compound recipe reserpine oral cavity disintegration tablet according to claim 1-8, it is characterized in that: first the reserpine of recipe quantity, cyclopenthiazide and hydroxypropyl cellulose are dissolved in ethanol, rest activity composition and fumaric acid add in fluidized bed granulation seed-coating machine, spray into above-mentioned alcoholic solution after fluidisation mixing to granulate, the alcoholic solution of polyacrylic resin IV is sprayed into after completing, terminate post-drying, add filler, disintegrating agent, correctives and mix lubricant after granulate evenly, tabletting and get final product;
(1) oral cavity disintegration tablet prescription
Reserpine 0.3g, hydralazine hydrochloride 10g, cyclopenthiazide 0.25g, hydrochlorothiazide 15g, promethazine hydrochloride 20g, potassium chloride 300g, rutin 50g, Arechin (Polfa) 25g, VB11 0g, vitamin B6 10g, fumaric acid 50g, polyacrylic resin IV200g, mannitol 913g, cross-linking sodium carboxymethyl cellulose 36g, hydroxypropyl cellulose 50g, aspartame 50g part and magnesium stearate 10g;
(2) preparation process
Take reserpine and the cyclopenthiazide of recipe quantity, add in 95% ethanol 1000ml, after stirring and dissolving to clarification, take the hydroxypropyl cellulose of recipe quantity, add in above-mentioned alcoholic solution, stir to clarify, for subsequent use, take the polyacrylic resin IV of recipe quantity, add in 95% ethanol 2000ml, after stirring and dissolving to clarification, for subsequent use, by hydralazine hydrochloride, hydrochlorothiazide, promethazine hydrochloride, potassium chloride, rutin, Arechin (Polfa), vitamin B
1, vitamin B
6pulverize respectively with fumaric acid, sieve 80 eye mesh screens, take the above-mentioned supplementary material of recipe quantity, after equal increments method mix homogeneously, add in fluidized bed granulation seed-coating machine, preheating, regulate stream temperature to 40 DEG C, dry air flow 100m
3* h
-1, get the hydroxypropyl cellulose alcoholic solution of above-mentioned active component, pump into aerochamber atomization with peristaltic pump with the flow velocity of top spray mode 5ml/min to granulate, atomizing pressure is 1.4bar, progressively improve and pump into speed and be finished to coating solution to 40ml/min, the alcoholic solution of polyacrylic resin IV is pumped into aerochamber atomization in top spray mode and granulates by continuation peristaltic pump, stream temperature is improved to 50 DEG C after terminating, continue fluidized drying in fluid bed to take out after 45 minutes, choose and be less than 18 order granules, after passed examination, add the filler of recipe quantity, disintegrating agent, after correctives mixes 30 minutes, add lubricant, mixing 5min, tabletting, pack.
10. the preparation method of the compound recipe reserpine oral cavity disintegration tablet according to claim 1-9, is characterized in that: the tablet pressure of gained is at more than 40N; This oral cavity disintegration tablet in the intraoral disintegration time within 30 seconds, and without bitter.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510732841.6A CN105213425A (en) | 2015-11-03 | 2015-11-03 | One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof |
| CN201610275594.6A CN105902564B (en) | 2015-11-03 | 2016-04-29 | A kind of pharmaceutical composition and preparation method for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510732841.6A CN105213425A (en) | 2015-11-03 | 2015-11-03 | One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105213425A true CN105213425A (en) | 2016-01-06 |
Family
ID=54982941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510732841.6A Pending CN105213425A (en) | 2015-11-03 | 2015-11-03 | One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213425A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920009A (en) * | 2016-05-24 | 2016-09-07 | 成都市斯贝佳科技有限公司 | Anti-hypertension medicine compound preparation for reducing systolic pressure to maximum degree |
| CN106619707A (en) * | 2016-10-12 | 2017-05-10 | 南京康凯生物科技有限公司 | Compound reserpine tablet for treating hypertension and preparation method thereof |
| CN108096203A (en) * | 2018-02-09 | 2018-06-01 | 常州康普药业有限公司 | A kind of promethazine hydrochloride piece and preparation method thereof |
| CN109745337A (en) * | 2017-11-07 | 2019-05-14 | 郑州泰丰制药有限公司 | Compound tetrazine Reserpine In Tablets and preparation method |
-
2015
- 2015-11-03 CN CN201510732841.6A patent/CN105213425A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105920009A (en) * | 2016-05-24 | 2016-09-07 | 成都市斯贝佳科技有限公司 | Anti-hypertension medicine compound preparation for reducing systolic pressure to maximum degree |
| CN106619707A (en) * | 2016-10-12 | 2017-05-10 | 南京康凯生物科技有限公司 | Compound reserpine tablet for treating hypertension and preparation method thereof |
| CN109745337A (en) * | 2017-11-07 | 2019-05-14 | 郑州泰丰制药有限公司 | Compound tetrazine Reserpine In Tablets and preparation method |
| CN108096203A (en) * | 2018-02-09 | 2018-06-01 | 常州康普药业有限公司 | A kind of promethazine hydrochloride piece and preparation method thereof |
| CN108096203B (en) * | 2018-02-09 | 2019-11-12 | 常州康普药业有限公司 | A kind of promethazine hydrochloride piece and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5053865B2 (en) | Method for producing orally disintegrating solid preparation | |
| ES2237121T3 (en) | FAST DISGREGABLE SOLID PREPARATION. | |
| CN105663064B (en) | A kind of imatinib mesylate stomach dissolution type pellet tablet and preparation method thereof | |
| JP2003514780A (en) | Pharmaceutical composition | |
| PT2258351E (en) | Granules containing lansoprazole in large amount | |
| ES2303314T3 (en) | PROLONGED RELEASE FORMULATIONS OF DIPIRIDAMOL AND PROCEDURE FOR PREPARATION. | |
| CN106511260B (en) | A kind of Berberine hydrochloride takes orally pellet xerogel and its preparation method and application | |
| UA110945C2 (en) | Oral pharmaceutical formulation comprising nalbuphine (variants) | |
| US20160045446A1 (en) | Oral administration preparation with masked bitterness of silodosin | |
| CN105007897A (en) | Suspension for oral administration comprising amorphous tolvaptan | |
| CN105213425A (en) | One treats hypertensive compound recipe reserpine oral cavity disintegration tablet and preparation method thereof | |
| EP3813831B1 (en) | Extended release compositions comprising trihexyphenidyl | |
| US20230240999A1 (en) | Novel fine particle coating (drug-containing hollow particle and method for manufacturing same) | |
| CN107693515B (en) | Pharmaceutical composition containing alkalizer and eltrombopag and application thereof | |
| US20150050336A1 (en) | Taste Masking System For Non-Plasticizing Drugs | |
| CN105193841A (en) | Compound reserpine medicine composition for treating hypertension and preparation method of compound reserpine medicine composition | |
| CN105902564B (en) | A kind of pharmaceutical composition and preparation method for treating hypertension | |
| CN105496967B (en) | Ranitidine hydrochloride controlled release dry suspensoid agent and preparation method thereof | |
| JP7359764B2 (en) | Granules containing diamine derivatives | |
| WO2005044238A1 (en) | Modified release solid dosage form of amphetamine salts | |
| CN109157527B (en) | Irbesartan capsule and preparation method thereof | |
| CN111617042A (en) | Composite calcium carbonate vitamin D3Water-free swallow granule and preparation method thereof | |
| RU2690685C2 (en) | Pharmaceutical compositions containing alpelisib | |
| JP4775879B2 (en) | Vitamin composition | |
| CN112312912B (en) | Granules containing diamine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160106 |